BACKGROUND: High-dose @entity288 are currently recommended for @entity1274 ( @entity1274 ) treatment. Intratympanic injections (ITI) are of growing importance, especially in cases of therapy resistance. The selection of @entity1 for this procedure in SSNHL has not been adequately examined so far. STUDY DESIGN: A total of 77 @entity1 with @entity1274 after ineffective systemic pretreatment underwent intratympanic administration of @entity619 and hyaluronic acid. Improvement after treatment was determined by pure tone audiometry for both ears before and of the treated ear after ITI. RESULTS: In this study 34 female and 43 male @entity1 with mean age of 57 years showed a pre-ITI @entity393 of 35  dB in the lower frequencies and 69  dB in the higher frequencies. The mean hearing gain was 10  dB and the response rate was 62   %. Absolute hearing gain revealed significant improvements at 500  Hz, 1  kHz and 2  kHz. Under inclusion of contralateral thresholds there were hardly any differences up to 4  kHz. In a detailed analysis of responders moderate improvements could be observed even in higher frequencies. Overall, no relevant adverse events occurred. CONCLUSION: Treatment of @entity1274 resistant to systemic regimens by ITI of @entity230 provides an option that offers additional prospects of auditory improvement for affected @entity1 . The presented results indicate that these modalities are also valid for @entity1 with pancochlear @entity1274 .

[Intratympanic injection therapy for therapy refractory acute XXXX : A safe option for secondary treatment].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone'] @entity1274 :: ('MESH:D006319', 'Disease') :: ['idiopathic sudden sensorineural hearing loss', 'ISSNHL'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids'] @entity393 :: ('MESH:D034381', 'Disease') :: ['hearing loss'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']
@entity393 :: (MESH:D034381,Disease) :: ['hearing loss']
